Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05542303 | A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects | PHASE1 | COMPLETED | 24 | — | — | Oct 16, 2022 | Apr 4, 2023 | Apr 6, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| ZB001 for injection | EXPERIMENTAL | Treated different dose cohorts with single intravenous injection of ZB001 |
| Name | Type | Description |
|---|---|---|
| ZB001 for injection | DRUG | Dose Cohort1 (3mg/kg) ZB001 of single IV injection |
Inclusion Criteria: 1. Healthy Chinese subjects between 18 and 55 years old (inclusive) at Screening 2. Free of any clinically significant disease or medical condition at screening as determinedby the Investigator 3. Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 32 kg/m2 4. Women m...